• Adverse event [ Time Frame: Part I: Baseline through end of treatment (up to a maximum of 30 days after last study drug intake) ; Part II Baseline through end of treatment (up to a maximum of 30 days after last study drug intake) ]
  Occurrence and severity of adverse events
• Change in Vital signs [ Time Frame: Part I: Day 1 pre-dose up to 6 hours post dose. Part II: Day 1 and Day 7 pre dose up to 6 hours post dose ]
  Change in Systolic and Diastolic blood pressure
• Heart Rate [ Time Frame: Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose ]
  Change in Heart Rate
• PR interval [ Time Frame: Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose ]
  Change in PR interval
• QRS interval [ Time Frame: Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose ]
  Change in QRS interval
• QTCf interval [ Time Frame: Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose ]
  Change in QTCf interval
• FEV1 [ Time Frame: Part I: Day 1 pre dose up to 6 hours post dose. Part II: Day 1 and Day 7 pre dose up to 6 hours post dose. Day 2 -6: pre dose up to 2 hours post dose ]
  Change in FEV1

• AUC [ Time Frame: Part I: Day 1. Part II Day 1-7 ]
  Area under the plasma concentration curve
• Cmax [ Time Frame: Part I: Day 1. Part II Day 1-7 ]
  Peak plasma concentration
• T max [ Time Frame: Part I: Day 1. Part II Day 1-7 ]
  Time to reach the maximum plasma concentration
• C24h [ Time Frame: Part II: Day 5 Day 6 ]
  Trough drug concentration 24 h post dose
• Rac [ Time Frame: Part II: Day 7 ]
  Accumulation ratio
• NE activity [ Time Frame: Part I: Day -1 Day 1. Part II: Day -1 - 7 ]
  Change in neutrophil elastase activity in sputum

CHF 6333 is a medicinal product on development for the treatment of cystic fibrosis and non-CF bronchiectasis and undergoing clinical testing. It has not yet been approved by the authorities for the treatment of these diseases.

CHF6333 is an inhaled anti-inflammatory which mechanism of action is based on the inhibition of Human Neutrofil Elastase.

The safety and tolerability of single and repeated ascending doses of inhaled CHF 6333 was previously investigated in healthy subjects: information was gathered on the uptake, distribution and excretion of the medicinal product being tested (pharmacokinetics). In this current clinical trial CHF 6333 will be tested in patients(CF and NCFB) for the first time.

Three dose level will be tested during the first part of the study, as single administration. One repeated dose will be administered in the second part of the study.

• Cystic Fibrosis
• Non-Cystic Fibrosis Bronchiectasis

• Drug: CHF 6333
  CHF 6333 - Part I - SAD CHF 6333 - Part II - MD
• Drug: Placebo
  Placebo - Part I - SAD Placebo Part II - MAD

• Experimental: CHF6333

  CHF6333 Active (part I - SAD). Once daily inhaled single dose of CHF6333 at each period (three dose level).

  CHF6333 Active (part II -MD). Once daily inhaled multiple dose of CHF6333 for 7 consecutive days.

  Intervention: Drug: CHF 6333
• Placebo Comparator: CHF6333 Placebo

  Part I (SAD): Single dose of placebo matching CHF6333 at each period

  Part II (MD): Once daily multiple doses of placebo matching CHF6333 for 7 consecutive days

  Intervention: Drug: Placebo

INCLUSION CRITERIA:

CF patients:

• Patient's written informed consent obtained prior to any study-related procedure;
• Male or female patient ≥ 18 years old with a confirmed historical diagnosis of cystic fibrosis;
• Ability to provide a spontaneous sputum sample at screening;
• Non- or ex-smokers who smoked < 10 pack years and stopped smoking > 1 year before screening visit;
• Patient in stable clinical condition and free from exacerbation for at least 4 weeks prior to screening and/or prior to randomisation;
• Patient on stable concomitant treatment regimen within 4 weeks prior to screening and/or prior to randomisation;
• Patient with pre-bronchodilator FEV1 ≥ 50% of predicted normal at screening and/or prior to randomisation;
• Vital signs within normal limits at screening and prior to randomisation;

NCFB patients:

• Patient's written informed consent obtained prior to any study-related procedure;
• Male or female patient ≥ 18 years old with a diagnosis of Bronchiectasis confirmed by a historical Chest CT;
• Presence of clinically significant symptoms related to Bronchiectasis, such as daily cough that occurs over months or years, daily production of large amount of sputum, shortness of breath, wheezing chest pain;
• Ability to provide a spontaneous sputum sample at screening;
• Non- or ex-smokers who smoked < 10 pack years and stopped smoking > 1 year before screening visit;
• Patients in stable clinical condition and free from exacerbation since at least 4 weeks before screening and/or prior to randomisation;
• Patients on stable concomitant treatment regimen within 4 weeks prior to screening and/or prior to randomisation
• Patient with pre- bronchodilator FEV1 ≥ 50% of predicted normal at screening and/or prior randomization visit;
• Vital signs within normal limits at screening and prior to randomisation

EXCLUSION CRITERIA CF Patients

• Patient with BMI ≤ 17
• History of a clinically meaningful unstable or uncontrolled chronic comorbidity in the opinion of the Investigator;
• Unstable pulmonary status or symptomatic respiratory tract infection and related changes in therapy for pulmonary disease as per Investigator's judgment within 4 weeks before screening or prior to randomisation;
• Abnormal and clinically significant 12-lead ECG at screening or prior to randomisation;
• History of asthma based on objective evidence;
• History of malignancy, solid organ/haematological transplantation;
• Patient with evidence of active Nontuberculous Mycobacteria (NTM) and Tuberculous Mycobacteria (TM) infection or related bronchiectasis in the past 12 months;
• Patient with a positive test for active Allergic Bronchopulmonary Aspergillosis (ABPA) infection confirmed at screening or patient withABPA related bronchiectasis.
• Pregnant or lactating women.
• Patient on non-steroidal anti-inflammatory drugs (NSAIDs) within 4 weeks prior to screening or prior to randomization visit.
• Patient on cystic fibrosis transmembrane conductance regulator (CFTR) modulators and correctors if not on stable treatment regimen for at least 3 months prior to screening or prior to randomization.
• Positive HIV1 or HIV2 serology at screening; Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening (i.e. positive HB surface antigen (HBsAg), HB core antibody (anti-HBc), HC antibody);

NCFB Patients

• Patient with BMI ≤ 17
• History of a clinically meaningful unstable or uncontrolled chronic comorbidity in the opinion of the Investigator;
• Unstable pulmonary status or symptomatic respiratory tract infection and related changes in therapy for pulmonary disease as per Investigator's judgment within 4 weeks before screening or prior to randomisation.
• Abnormal and clinically significant 12-lead ECG at screening or prior to randomisation that results in active medical problem which may impact the safety of the patients as per Investigator's judgment.
• History of malignancy, solid organ/haematological transplantation;
• Known diagnosis of cystic fibrosis. A negative sweat test is required at screening (sweat chloride should be < 40 mmol/L);
• History of asthma based on objective evidence of the condition;
• Patient with primary diagnosis of COPD in the opinion of theInvestigator;
• Patient with rheumatoid factor positivity;
• Patient with evidence of active Nontuberculous Mycobacteria (NTM) and Tuberculous Mycobacteria (TM) infection or related bronchiectasis in the past 12 months;
• Patient with a positive test for active Allergic Bronchopulmonary Aspergillosis (ABPA) infection confirmed at screening or patient with ABPA related bronchiectasis;
• Patient with Connective Tissue Disease (CTD) related bronchiectasis;
• Diagnosis of common variable immunodeficiency (CVID);
• Patient on any antibiotics (except for stable macrolides treatment),oral, inhaled and IV, within 4 weeks prior to screening or prior to randomisation;
• Patient on oral corticosteroids within 4 weeks prior to screening visit or prior to randomization.
• Patient on non-steroidal anti-inflammatory drugs (NSAIDs) within 4 weeks prior to screening or randomization visit.
• Patient on Carbocysteine and Mannitol treatment within 4 weeks before the screening or randomization visit.
• Patient with traction bronchiectasis;
• Patient with any condition that prevent them to use inhaledantibiotics (including patients who previously experienced adverse reaction to inhaled antibiotics;
• Patient treated with monoclonal antibodies (mAb);
• Pregnant or lactating women.
• Positive HIV1 or HIV2 serology at screening; Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening (i.e. positive HB surface antigen (HBsAg), HBcore antibody (anti-HBc), HC antibody).